Last reviewed · How we verify
TT-00973-MS tablets treatment — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TT-00973-MS tablets treatment (TT-00973-MS tablets treatment) — TransThera Sciences (Nanjing), Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TT-00973-MS tablets treatment TARGET | TT-00973-MS tablets treatment | TransThera Sciences (Nanjing), Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TT-00973-MS tablets treatment CI watch — RSS
- TT-00973-MS tablets treatment CI watch — Atom
- TT-00973-MS tablets treatment CI watch — JSON
- TT-00973-MS tablets treatment alone — RSS
Cite this brief
Drug Landscape (2026). TT-00973-MS tablets treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/tt-00973-ms-tablets-treatment. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab